Journal Article Summary
The article investigates patient experiences and perceptions regarding the off-label use of Ozempic (semaglutide) for weight loss, a topic of increasing relevance due to the rising prevalence of obesity and related health issues. While Ozempic is primarily approved for managing type 2 diabetes, its appetite-suppressing effects have led many to use it for weight loss. Understanding how patients weigh the benefits against potential side effects is crucial for optimizing treatment adherence and outcomes, especially since existing research often focuses on clinical trial populations rather than real-world experiences.
The study analyzed 60 anonymous user reviews from Drugs.com, focusing on individuals who reported using Ozempic for weight loss. Through thematic analysis, three main themes emerged: changes in body weight and appetite, non-weight-related symptoms and side effects, and intentions regarding ongoing use versus discontinuation. The findings revealed that two-thirds of respondents experienced reduced appetite or weight loss, while gastrointestinal side effects were common but did not significantly impact overall satisfaction. Instead, lack of weight loss and the emergence of other side effects were more closely linked to lower satisfaction and plans to discontinue treatment.
Limitations of the study include the self-selected nature of the sample and the absence of demographic or clinical data, which may affect the generalizability of the findings. Patients should be aware that while many users report effective weight loss, side effects can vary in severity and may influence treatment decisions. It is essential for individuals considering or currently using Ozempic to discuss their experiences and any concerns with a healthcare professional to ensure safe and effective management of their weight loss journey.
Medical Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Armanious Abanoub J, Hunter Rachel-Mae, Griffiths Kristi R, Bowrey Hannah E, Brown Robyn M, James Morgan H. Patient Perceptions of Ozempic (Semaglutide) for Weight Loss: Mixed Methods Analysis of Online Medication Reviews. Journal of Medical Internet Research 2026. DOI: 10.2196/78391. PMID: 41512288. PMCID: PMC12904099.
Featured Pill Pals Product
Semaglutide with B-12 --- 10 mg / 2 mg / 4 ml --- 4 ml vial --- Weight Loss Glucagon-Like Peptide-1 (GLP-1)
Semaglutide with B-12 — 10 mg / 2 mg / 4 ml — 4 ml vial — Weight Loss Glucagon-Like Peptide-1 (GLP-1) is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription required.
Request a prescription transfer and our pharmacy team will help coordinate the next step.
